BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 22982525)

  • 1. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
    Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
    Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
    Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of guanidino analogues of roscovitine.
    Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
    Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.
    Trova MP; Barnes KD; Alicea L; Benanti T; Bielaska M; Bilotta J; Bliss B; Duong TN; Haydar S; Herr RJ; Hui Y; Johnson M; Lehman JM; Peace D; Rainka M; Snider P; Salamone S; Tregay S; Zheng X; Friedrich TD
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6613-7. PubMed ID: 19854650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
    Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
    J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.
    Oumata N; Bettayeb K; Ferandin Y; Demange L; Lopez-Giral A; Goddard ML; Myrianthopoulos V; Mikros E; Flajolet M; Greengard P; Meijer L; Galons H
    J Med Chem; 2008 Sep; 51(17):5229-42. PubMed ID: 18698753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
    Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
    Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
    Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
    Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
    Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
    Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS; Ismail NS; Elzahabi HS
    Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.
    Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
    Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
    Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives.
    Verones V; Flouquet N; Farce A; Carato P; Leonce S; Pfeiffer B; Berthelot P; Lebegue N
    Eur J Med Chem; 2010 Dec; 45(12):5678-84. PubMed ID: 20884092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and synthesis of purine inhibitors of CDK2. III.
    Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.